

Runken, M. Chris et al.

**Article**

## The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain

Health Economics Review

**Provided in Cooperation with:**

Springer Nature

*Suggested Citation:* Runken, M. Chris et al. (2019) : The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain, Health Economics Review, ISSN 2191-1991, Springer, Heidelberg, Vol. 9, Iss. 22, pp. 1-10,  
<https://doi.org/10.1186/s13561-019-0237-7>

This Version is available at:

<https://hdl.handle.net/10419/285135>

**Standard-Nutzungsbedingungen:**

Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Zwecken und zum Privatgebrauch gespeichert und kopiert werden.

Sie dürfen die Dokumente nicht für öffentliche oder kommerzielle Zwecke vervielfältigen, öffentlich ausstellen, öffentlich zugänglich machen, vertreiben oder anderweitig nutzen.

Sofern die Verfasser die Dokumente unter Open-Content-Lizenzen (insbesondere CC-Lizenzen) zur Verfügung gestellt haben sollten, gelten abweichend von diesen Nutzungsbedingungen die in der dort genannten Lizenz gewährten Nutzungsrechte.

**Terms of use:**

*Documents in EconStor may be saved and copied for your personal and scholarly purposes.*

*You are not to copy documents for public or commercial purposes, to exhibit the documents publicly, to make them publicly available on the internet, or to distribute or otherwise use the documents in public.*

*If the documents have been made available under an Open Content Licence (especially Creative Commons Licences), you may exercise further usage rights as specified in the indicated licence.*



<https://creativecommons.org/licenses/by/4.0/>

CORRECTION

Open Access



# Correction to: The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain

M. Chris Runken<sup>1</sup>, Paolo Caraceni<sup>2</sup>, Javier Fernandez<sup>3,4</sup>, Alexander Zipprich<sup>5</sup>, Rashad Carlton<sup>6\*</sup> and Martin Bunke<sup>7</sup>

**Correction to:** *Health Economics Review* (2019) 9:22  
<https://doi.org/10.1186/s13561-019-0237-7>

Following publication of the original article [1], the authors reported that one of the numbers within Fig. 6 contains a mistake.

The correct Fig. 6 is shown below.

#### Author details

<sup>1</sup>Grifols Shared Services North America (SSNA), Inc, Research Triangle Park, Raleigh, NC, USA. <sup>2</sup>Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. <sup>3</sup>Liver ICU, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain. <sup>4</sup>European Foundation of Chronic Liver Failure (EF-Clif), Barcelona, Spain. <sup>5</sup>Department of Internal Medicine I, Martin-Luther-University Halle-Wittenberg, Halle, Germany. <sup>6</sup>Xcenda L.L.C, Palm Harbor, FL, USA. <sup>7</sup>Senior Director Medical Affairs, Retrophin, San Diego, CA, USA.

Published online: 17 April 2020

#### Reference

1. Runken, et al. The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain. *Health Economics Review*. 2019;9:22. <https://doi.org/10.1186/s13561-019-0237-7>.


\* Correspondence: [rashad.carlton@xcenda.com](mailto:rashad.carlton@xcenda.com)

The original article can be found online at <https://doi.org/10.1186/s13561-019-0237-7>

<sup>6</sup>Xcenda L.L.C, Palm Harbor, FL, USA



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



**Fig. 6** Expected cost of treatment of the different strategies for SBP